These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 23873876)

  • 1. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases.
    Duru N; van der Goes MC; Jacobs JW; Andrews T; Boers M; Buttgereit F; Caeyers N; Cutolo M; Halliday S; Da Silva JA; Kirwan JR; Ray D; Rovensky J; Severijns G; Westhovens R; Bijlsma JW
    Ann Rheum Dis; 2013 Dec; 72(12):1905-13. PubMed ID: 23873876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice.
    van der Goes MC; Jacobs JW; Boers M; Andrews T; Blom-Bakkers MA; Buttgereit F; Caeyers N; Cutolo M; Da Silva JA; Guillevin L; Kirwan JR; Rovensky J; Severijns G; Webber S; Westhovens R; Bijlsma JW
    Ann Rheum Dis; 2010 Nov; 69(11):1913-9. PubMed ID: 20693273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.
    Hoes JN; Jacobs JW; Boers M; Boumpas D; Buttgereit F; Caeyers N; Choy EH; Cutolo M; Da Silva JA; Esselens G; Guillevin L; Hafstrom I; Kirwan JR; Rovensky J; Russell A; Saag KG; Svensson B; Westhovens R; Zeidler H; Bijlsma JW
    Ann Rheum Dis; 2007 Dec; 66(12):1560-7. PubMed ID: 17660219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.
    van der Goes MC; Jacobs JW; Boers M; Andrews T; Blom-Bakkers MA; Buttgereit F; Caeyers N; Choy EH; Cutolo M; Da Silva JA; Guillevin L; Holland M; Kirwan JR; Rovensky J; Saag KG; Severijns G; Webber S; Westhovens R; Bijlsma JW
    Ann Rheum Dis; 2010 Jun; 69(6):1015-21. PubMed ID: 19762359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Glucocorticoids in rheumatic diseases - what is the optimal dose?].
    Krause D
    Dtsch Med Wochenschr; 2012 Sep; 137(36):1751-4. PubMed ID: 22933199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward safer treatment with glucocorticoids: via patient and rheumatologist perspectives to recommendations on monitoring for adverse events.
    van der Goes MC; Jacobs JW; Bijlsma JW
    Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S116-20. PubMed ID: 22018196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
    Zhang W; Doherty M; Arden N; Bannwarth B; Bijlsma J; Gunther KP; Hauselmann HJ; Herrero-Beaumont G; Jordan K; Kaklamanis P; Leeb B; Lequesne M; Lohmander S; Mazieres B; Martin-Mola E; Pavelka K; Pendleton A; Punzi L; Swoboda B; Varatojo R; Verbruggen G; Zimmermann-Gorska I; Dougados M;
    Ann Rheum Dis; 2005 May; 64(5):669-81. PubMed ID: 15471891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety of low-dose glucocorticoids in rheumatic diseases: results from observational studies.
    Hwang YG; Saag K
    Neuroimmunomodulation; 2015; 22(1-2):72-82. PubMed ID: 25228230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
    Zhang W; Doherty M; Leeb BF; Alekseeva L; Arden NK; Bijlsma JW; Dinçer F; Dziedzic K; Häuselmann HJ; Herrero-Beaumont G; Kaklamanis P; Lohmander S; Maheu E; Martín-Mola E; Pavelka K; Punzi L; Reiter S; Sautner J; Smolen J; Verbruggen G; Zimmermann-Górska I
    Ann Rheum Dis; 2007 Mar; 66(3):377-88. PubMed ID: 17046965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.
    Strehl C; Bijlsma JW; de Wit M; Boers M; Caeyers N; Cutolo M; Dasgupta B; Dixon WG; Geenen R; Huizinga TW; Kent A; de Thurah AL; Listing J; Mariette X; Ray DW; Scherer HU; Seror R; Spies CM; Tarp S; Wiek D; Winthrop KL; Buttgereit F
    Ann Rheum Dis; 2016 Jun; 75(6):952-7. PubMed ID: 26933146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal insufficiency after glucocorticoid withdrawal in children with rheumatic diseases.
    Huber BM; Bolt IB; Sauvain MJ; Flück CE
    Acta Paediatr; 2010 Dec; 99(12):1889-93. PubMed ID: 20649769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Benefits and risks of glucocorticoid therapy for the treatment of rheumatoid arthritis and management of glucocorticoid-induced osteoporosis].
    Suzuki Y; Wakabayashi T; Saito E; Yamada C; Suwa A
    Clin Calcium; 2009 Mar; 19(3):404-15. PubMed ID: 19252251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists.
    Sidiropoulos PI; Hatemi G; Song IH; Avouac J; Collantes E; Hamuryudan V; Herold M; Kvien TK; Mielants H; Mendoza JM; Olivieri I; Østergaard M; Schachna L; Sieper J; Boumpas DT; Dougados M
    Rheumatology (Oxford); 2008 Mar; 47(3):355-61. PubMed ID: 18276738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based recommendations for the role of exercise in the management of osteoarthritis of the hip or knee--the MOVE consensus.
    Roddy E; Zhang W; Doherty M; Arden NK; Barlow J; Birrell F; Carr A; Chakravarty K; Dickson J; Hay E; Hosie G; Hurley M; Jordan KM; McCarthy C; McMurdo M; Mockett S; O'Reilly S; Peat G; Pendleton A; Richards S
    Rheumatology (Oxford); 2005 Jan; 44(1):67-73. PubMed ID: 15353613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
    Zhang W; Doherty M; Pascual E; Bardin T; Barskova V; Conaghan P; Gerster J; Jacobs J; Leeb B; Lioté F; McCarthy G; Netter P; Nuki G; Perez-Ruiz F; Pignone A; Pimentão J; Punzi L; Roddy E; Uhlig T; Zimmermann-Gòrska I;
    Ann Rheum Dis; 2006 Oct; 65(10):1301-11. PubMed ID: 16707533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research.
    Avouac J; Kowal-Bielecka O; Landewe R; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):629-34. PubMed ID: 18957486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. United States adults meeting 2010 American College of Rheumatology criteria for treatment and prevention of glucocorticoid-induced osteoporosis.
    Overman RA; Toliver JC; Yeh JY; Gourlay ML; Deal CL
    Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1644-52. PubMed ID: 24719294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of low-dose glucocorticoids in rheumatic diseases.
    Hwang YG; Saag K
    Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S104-12. PubMed ID: 22018194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Problems related to systemic glucocorticoid therapy in children.
    Melo-Gomes JA
    J Rheumatol Suppl; 1993 Apr; 37():35-9. PubMed ID: 8501750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients].
    Gómez Reino J; Loza E; Andreu JL; Balsa A; Batlle E; Cañete JD; Collantes Estévez E; Fernández Carballido C; Fernández Sueiro JL; García de Vicuña R; González-Álvaro I; González Fernández C; Juanola X; Linares LF; Marenco JL; Martín Mola E; Moreno Ramos M; Mulero Mendoza J; Muñoz Fernández S; Queiro R; Richi Alberti P; Sanz J; Tornero Molina J; Zarco Montejo P; Carmona L;
    Reumatol Clin; 2011; 7(5):284-98. PubMed ID: 21925444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.